

- To:
- CCG heads of medicines optimisation/medicines management
 - NHS trust and foundation trust chief pharmacists

NHS England and NHS Improvement
Skipton House
80 London Road
London
SE1 6LH

- cc:
- CCG prescribing leads
 - CCG accountable officers
 - NHS England and NHS Improvement regional chief pharmacists

22 September 2021

Dear Colleagues,

Information for medicines optimisation leads: Inclisiran (Leqvio)

On Wednesday 1 September 2021, NICE published a positive [final appraisal document](#) (FAD) for Inclisiran. The commercial deal agreed with NHS England meant that this treatment is now a clinically and cost effective treatment option for a broader patient population.

Inclisiran is recommended as an option for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults.

It is recommended only if:

- There is a history of any of the following cardiovascular events:
 - Acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation),
 - Coronary or other arterial revascularisation procedures
 - Coronary heart disease
 - Ischaemic stroke or
 - Peripheral arterial disease, and
- Low density lipoprotein cholesterol (LDL-C) concentrations are persistently 2.6 mmol/l or more, despite maximum tolerated lipid lowering therapy.

To support timely access to this treatment, the Accelerated Access Collaborative (AAC) and Commercial Medicines Directorate at NHS England have put together the attached Medicines Optimisation Pack for medicines optimisation leads.

Please can you cascade the attached **Medicines Optimisation Pack** to medicines optimisation leads within your region in order to support timely review of Inclisiran by Area Prescribing Committees or any other local bodies as required for formulary access, including RMOCs.

Key points for information:

- NHS England is making central funding available for inclisiran from release of the NICE FAD (01.09.2021) so that local finances are not a barrier to the local uptake of inclisiran
- Although mainly funded centrally, a 'nominal' price (charge) has been agreed that will be funded from the CCG budget
- Routine funding of inclisiran is to be available within 30-days of the publication of the NICE FAD
- The Accelerated Access Collaborative and Academic Health Science Networks will work with system leaders to support the implementation of inclisiran within a primary care setting
- Further information about inclisiran and the funding arrangements can be found in the attached medicines optimisation pack

Key points for action:

- Rapid convening of local area prescribing committees to review and adopt inclisiran
- Listing inclisiran within the local formulary in line with NICE guidance set out in the FAD
- Listing inclisiran with a green status on your local formulary to allow prescribing by GPs and independent prescribers in the primary care team
- Allocation of funding to GP prescribing budgets to fund inclisiran at the nominal price in line with anticipated uptake

If you have any questions, please contact: england.lipidsphm@nhs.net.

Yours sincerely,



Matt Whitty

Director of Innovation, Research and Life Sciences; Chief Executive of the Accelerated Access Collaborative
NHS England and NHS Improvement



Blake Dark

Interim Chief Commercial Officer
NHS England and NHS Improvement